Pelger-Huët anomaly (PHA), an autosomal dominant haematological trait is characterised by neutrophil nuclear hypolobulation and modified chromatin distribution. Mutations in the lamin B receptor gene, a member of the sterol reductase family have been identified as the underlying cause. Due to its asymptomatic nature or lack of observer familiarity, PHA is often overlooked. In this review, we give an overview of the main pathophysiological, clinical, morphological and functional aspects of PHA. Furthermore, we highlight the importance of a comprehensive approach to the assessment of this laminopathy.

1.
Oosterwijk JC, Mansour S, van Noort G, Waterham HR, Hall CM, Hennekam RC: Congenital abnormalities reported in Pelger-Huët homozygosity as compared to Greenberg/HEM dysplasia: highly variable expression of allelic phenotypes. J Med Genet 2003;40:937–941.
2.
Pelger K: Demonstratie van een paar zeldzaam voorkomende typen van bloedlichaampjes en bespreking der patiënten. Ned Tijdschr Geneeskd 1928;72:1178.
3.
Huët GJ: Ueber eine bisher unbekannte familiaere Anomalie der Leukocyten. Klin Wochenschr 1932;11:1264–1266.
4.
Hoffmann K, Sperling K, Olins AL, Olins DE: The granulocyte nucleus and lamin B receptor: avoiding the ovoid. Chromosoma 2007;116:227–235.
5.
Hoffmann K, Dreger CK, Olins AL, Olins DE, Shultz LD, Lucke B, Karl H, Kaps R, Müller D, Vayá A, Aznar J, Ware RE, Sotelo Cruz N, Lindner TH, Herrmann H, Reis A, Sperling K: Mutations in the gene encoding the lamin B receptor produce an altered nuclear morphology in granulocytes (Pelger-Huët anomaly). Nat Genet 2002;31:410–414.
6.
Worman HJ, Yuan J, Blobel G, Georgatos SD: A lamin B receptor in the nuclear envelope. Proc Natl Acad Sci USA 1988;85:8531–8534.
7.
Wydner KL, McNeil JA, Lin F, Worman HJ, Lawrence JB: Chromosomal assignment of human nuclear envelope protein genes LMNA, LMNB1, and LBR by fluorescence in situ hybridization. Genomics 1996;32:474–478.
8.
Schuler E, Lin F, Worman HJ: Characterization of the human gene encoding LBR, an integral protein of the nuclear envelope inner membrane. J Biol Chem 1994;269:11312–11317.
9.
Appelbaum J, Blobel G, Georgatos SD: In vivo phosphorylation of the lamin B receptor. Binding of lamin B to its nuclear membrane receptor is affected by phosphorylation. J Biol Chem 1990;265:4181–4184.
10.
Holmer L, Pezhman A, Worman HJ: The human lamin B receptor/sterol reductase multigene family. Genomics 1998;54:469–476.
11.
Best S, Salvati F, Kallo J, Garner C, Height S, Thein SL, Rees DC: Lamin B-receptor mutations in Pelger-Huët anomaly. Br J Haematol 2003;123:542–544.
12.
Olins AL, Olins DE: Cytoskeletal influences on nuclear shape in granulocytic HL-60 cells. BMC Cell Biol 2004;5:30.
13.
Makatsori D, Kourmouli N, Polioudaki H, Shultz LD, McLean K, Theodoropoulos PA, Singh PB, Georgatos SD: The inner nuclear membrane protein lamin B receptor forms distinct microdomains and links epigenetically marked chromatin to the nuclear envelope. J Biol Chem 2004;279:25567–25573.
14.
Haverkamp Begemann N, Van Lookeren Campagne A: Homozygous form of Pelger-Huët’s nuclear anomaly in man. Acta Haematol 1952;7:295–303.
15.
Shultz LD, Lyons BL, Burzenski LM, Gott B, Samuels R, Schweitzer PA, Dreger C, Herrmann H, Kalscheuer V, Olins AL, Olins DE, Sperling K, Hoffmann K: Mutations at the mouse ichthyosis locus are within the lamin B receptor gene: a single gene model for human Pelger-Huët anomaly. Hum Mol Genet 2003;12:61–69.
16.
Waterham HR, Koster J, Mooyer P, Noort Gv G, Kelley RI, Wilcox WR, Wanders RJ, Hennekam RC, Oosterwijk JC: Autosomal recessive HEM/Greenberg skeletal dysplasia is caused by 3 β-hydroxysterol δ 14-reductase deficiency due to mutations in the lamin B receptor gene. Am J Hum Genet 2003;72:1013–1017.
17.
Constantino BT: Pelger-Huët anomaly – morphology, mechanism, and significance in the peripheral blood film. Lab Med 2005;36:103–107.
18.
Harm H: Zur Klassifizierung und Vererbung der Neutrophilin-Kernform bei Mensch und Kaninchen. Blut 1955;1:3–25.
19.
Wilkinson PC: Assays of leukocyte locomotion and chemotaxis. J Immunol Methods 1998;216:139–153.
20.
Repo H, Vuopio P, Leirisalo M, Jansson SE, Kosunen TU: Impaired neutrophil chemotaxis in Pelger-Huët anomaly. Clin Exp Immunol 1979;36:326–333.
21.
Johnson CA, Bass DA, Trillo AA, Snyder MS, DeChatelet LR: Functional and metabolic studies of polymorphonuclear leukocytes in the congenital Pelger-Huet anomaly. Blood 1980;55:466–469.
22.
Latimer KS, Kircher IM, Lindl PA, Dawe DL, Brown J: Leukocyte function in Pelger-Huët anomaly of dogs. J Leukoc Biol 1989;45:301–310.
23.
Djaldetti M, Weiss S, Gafter U: Ultrastructural features of the blood cells in a patient with Pelger-Huët anomaly. Am J Clin Pathol 1976;65:942–947.
24.
Davidson WM, Lawler SD, Ackerley AG: The Pelger-Huët anomaly: investigation of family A. Ann Hum Genet 1954;19:1–9.
25.
Skendzel LP, Hoffman GC: The Pelger anomaly of leukocytes: forty-one cases in seven families. Am J Clin Pathol 1962;37:294–301.
26.
Shetty VT, Mundle SD, Raza A: Pseudo Pelger-Huët anomaly in myelodysplastic syndrome: hyposegmented apoptotic neutrophil? Blood 2001;98:1273–1275.
27.
Cunningham I, MacCallum SJ, Nicholls MD, Byth K, Hewson JW, Arnold B, Motum PI, Mulligan SP, Crane GG: The myelodysplastic syndromes: an analysis of prognostic factors in 226 cases from a single institution. Br J Haematol 1995;90:602–606.
28.
Shetty V, Hussaini S, Broady-Robinson L, Allampallam K, Mundle S, Borok R, Broderick E, Mazzoran L, Zorat F, Raza A: Intramedullary apoptosis of hematopoietic cells in myelodysplastic syndrome patients can be massive: apoptotic cells recovered from high-density fraction of bone marrow aspirates. Blood 2000;96:1388–1392.
29.
Kitagawa M, Saito I, Kuwata T, Yoshida S, Yamaguchi S, Takahashi M, Tanizawa T, Kamiyama R, Hirokawa K: Overexpression of tumor necrosis factor (TNF)-α and interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 1997;11:2049–2054.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.